BIOIVT, LLC

BIOIVT, LLC specializes in the manufacturing and supply of high-purity human and non-human primate biological specimens and related research materials for preclinical and translational science applications. The company’s core capabilities center on the collection, processing, cryopreservation, and quality-controlled distribution of hepatocytes, cerebrospinal fluid, serum, urine, and other biofluids from human and cynomolgus monkey sources, with particular expertise in cryoplateable cell systems and transporter substrate assays. Their technical proficiency spans advanced cell biology, biobanking protocols, and bioanalytical sample integrity management, serving as a critical enabler for drug metabolism, toxicology, and pharmacokinetic studies. BIOIVT’s differentiation lies in its ability to deliver consistently viable, phenotypically characterized primary cells and biofluids tailored to the rigorous standards of regulatory and academic research environments. The company maintains a strong, recurring relationship with the Department of Health and Human Services and the Department of Defense, providing essential biological reagents for NIH-funded translational research, military medical countermeasure development, and biomedical innovation programs. Work for HHS often supports the National Center for Advancing Translational Sciences and other intramural research initiatives, while DoD contracts focus on biothreat modeling and pharmacological screening using primate models. BIOIVT operates primarily under NAICS 325414, specializing in the manufacturing of biological products excluding diagnostics, with secondary activity in testing laboratory services for in vitro pharmacological assessments. Their market positioning is as a niche supplier of high-integrity human and non-human primate biospecimens critical to early-stage drug development and safety evaluation. BIOIVT, LLC is a privately held entity headquartered in Westbury, New York, with no federal certifications on record. Its geographic footprint is centered in the U.S. biopharma corridor, serving federal and institutional research clients nationwide through a focused, supply-chain-driven model.